SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 30, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 p.m. ET in New York.
David. R. Parkinson, President, and Chief Executive Officer and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings.
A live webcast of the presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com, and follow us on Twitter and LinkedIn.
ESSA Pharma, Inc.
Peter Virsik, Chief Operating Officer
778.331.0962
This email address is being protected from spambots. You need JavaScript enabled to view it.';document.getElementById('cloak888fd931927ab7a8870a63ffb862eb01').innerHTML += ''+addy_text888fd931927ab7a8870a63ffb862eb01+'<\/a>';
Investors and Media:
Argot Partners
212.600.1902
This email address is being protected from spambots. You need JavaScript enabled to view it.';document.getElementById('cloak334327323c764175aa26bd24ea274f2a').innerHTML += ''+addy_text334327323c764175aa26bd24ea274f2a+'<\/a>'; This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.20 |
Daily Volume: | 0 |
Market Cap: | US$9.320M |
October 06, 2025 February 11, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load